Walthausen & Company Has Raised Its Position in Camden National (CAC) by $2.34 Million as Market Valuation Rose; Proquest Associates Iv Has Lowered Immune Design Corp. (IMDZ) Stake by $530,658

April 16, 2018 - By Linda Rogers

Camden National Corporation (NASDAQ:CAC) Logo

Walthausen & Company increased its stake in Camden National Corp (CAC) by 95.77% based on its latest 2017Q4 regulatory filing with the SEC. Walthausen & Company bought 55,617 shares as the company’s stock rose 1.46% while stock markets declined. The institutional investor held 113,689 shares of the major banks company at the end of 2017Q4, valued at $4.79M, up from 58,072 at the end of the previous reported quarter. Walthausen & Company who had been investing in Camden National Corp for a number of months, seems to be bullish on the $693.26 million market cap company. The stock increased 1.07% or $0.47 during the last trading session, reaching $44.51. About 21,181 shares traded. Camden National Corporation (NASDAQ:CAC) has risen 3.55% since April 16, 2017 and is uptrending. It has underperformed by 8.00% the S&P500.

Proquest Associates Iv Llc decreased its stake in Immune Design Corp. (IMDZ) by 12.52% based on its latest 2017Q4 regulatory filing with the SEC. Proquest Associates Iv Llc sold 176,886 shares as the company’s stock declined 10.42% with the market. The institutional investor held 1.24M shares of the major pharmaceuticals company at the end of 2017Q4, valued at $4.82M, down from 1.41M at the end of the previous reported quarter. Proquest Associates Iv Llc who had been investing in Immune Design Corp. for a number of months, seems to be less bullish one the $180.47M market cap company. The stock increased 4.17% or $0.15 during the last trading session, reaching $3.75. About 369,907 shares traded. Immune Design Corp. (NASDAQ:IMDZ) has declined 53.26% since April 16, 2017 and is downtrending. It has underperformed by 64.81% the S&P500.

Among 5 analysts covering Immune Design (NASDAQ:IMDZ), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Immune Design had 11 analyst reports since August 18, 2015 according to SRatingsIntel. Jefferies initiated Immune Design Corp. (NASDAQ:IMDZ) rating on Wednesday, September 9. Jefferies has “Buy” rating and $30 target. On Monday, June 26 the stock rating was maintained by Jefferies with “Buy”. The stock has “Market Perform” rating by Wells Fargo on Wednesday, October 18. Cowen & Co maintained the stock with “Buy” rating in Tuesday, June 6 report. Jefferies maintained Immune Design Corp. (NASDAQ:IMDZ) rating on Thursday, March 15. Jefferies has “Buy” rating and $8.0 target. As per Tuesday, August 18, the company rating was initiated by Leerink Swann. The firm has “Buy” rating given on Thursday, October 5 by Jefferies. The firm has “Buy” rating by Jefferies given on Wednesday, August 10. Jefferies maintained Immune Design Corp. (NASDAQ:IMDZ) rating on Monday, September 4. Jefferies has “Buy” rating and $18.0 target.

Since October 27, 2017, it had 2 insider buys, and 5 sales for $21.92 million activity. On Thursday, January 4 the insider ter Meulen Jan Henrik sold $8,282. 3,328 shares were sold by Brady Stephen R, worth $13,885. 675 shares valued at $2,816 were sold by Yurasov Sergey on Thursday, January 4. $10.99 million worth of Immune Design Corp. (NASDAQ:IMDZ) was bought by Svennilson Peter on Friday, October 27. Another trade for 1,986 shares valued at $8,282 was sold by Gombotz Wayne. $33,247 worth of Immune Design Corp. (NASDAQ:IMDZ) shares were sold by Paya Carlos V.

Investors sentiment increased to 1.92 in Q4 2017. Its up 0.65, from 1.27 in 2017Q3. It increased, as 14 investors sold IMDZ shares while 12 reduced holdings. 24 funds opened positions while 26 raised stakes. 23.09 million shares or 94.39% more from 11.88 million shares in 2017Q3 were reported. Citigroup Inc has invested 0% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ). 16,398 are held by Rhumbline Advisers. Price T Rowe Associates Incorporated Md holds 0% of its portfolio in Immune Design Corp. (NASDAQ:IMDZ) for 34,948 shares. Fincl Bank Of Mellon stated it has 122,073 shares or 0% of all its holdings. Moore Capital Mngmt Limited Partnership accumulated 100,000 shares or 0.01% of the stock. Franklin Resources Incorporated owns 3.23M shares for 0.01% of their portfolio. Tiaa Cref Investment Mngmt stated it has 63,192 shares or 0% of all its holdings. Deutsche Bancorporation Ag accumulated 72,278 shares. Drw Limited Liability Company has invested 0.01% in Immune Design Corp. (NASDAQ:IMDZ). Bain Capital Pub Equity Mngmt Ltd Com has invested 0.93% in Immune Design Corp. (NASDAQ:IMDZ). 5,083 are held by Barclays Public Limited Com. American Intl Grp Inc has invested 0% in Immune Design Corp. (NASDAQ:IMDZ). Pnc reported 113 shares or 0% of all its holdings. Moreover, Numeric Investors Lc has 0% invested in Immune Design Corp. (NASDAQ:IMDZ) for 26,400 shares. Focused Wealth Mgmt Inc has invested 0% in Immune Design Corp. (NASDAQ:IMDZ).

Walthausen & Company, which manages about $1.45 billion and $1.06B US Long portfolio, decreased its stake in Itt Corporation by 6,230 shares to 136,120 shares, valued at $7.27 million in 2017Q4, according to the filing. It also reduced its holding in Aptar Group Inc (NYSE:ATR) by 3,690 shares in the quarter, leaving it with 68,968 shares, and cut its stake in Westlake Chemical Corp (NYSE:WLK).

Among 3 analysts covering Camden National Corp. (NASDAQ:CAC), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Camden National Corp. had 11 analyst reports since September 14, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, October 3 by Keefe Bruyette & Woods. As per Tuesday, August 8, the company rating was maintained by Piper Jaffray. Keefe Bruyette & Woods maintained the shares of CAC in report on Thursday, June 1 with “Buy” rating. Piper Jaffray maintained the shares of CAC in report on Friday, December 4 with “Overweight” rating. PiperJaffray maintained the shares of CAC in report on Friday, February 2 with “Overweight” rating. The stock of Camden National Corporation (NASDAQ:CAC) earned “Buy” rating by Piper Jaffray on Tuesday, October 31. Piper Jaffray initiated the stock with “Overweight” rating in Wednesday, September 16 report. Keefe Bruyette & Woods downgraded Camden National Corporation (NASDAQ:CAC) rating on Wednesday, November 1. Keefe Bruyette & Woods has “Hold” rating and $46.0 target. Keefe Bruyette & Woods initiated it with “Outperform” rating and $47 target in Monday, September 14 report. The firm earned “Hold” rating on Thursday, December 21 by Keefe Bruyette & Woods.

Since February 27, 2018, it had 5 buys, and 1 insider sale for $65,624 activity. DUFOUR GREGORY A sold $60,284 worth of Camden National Corporation (NASDAQ:CAC) on Tuesday, February 27. 331 shares were bought by Rose Patricia A, worth $9,980 on Thursday, March 15. JORDAN DEBORAH A also bought $28,974 worth of Camden National Corporation (NASDAQ:CAC) on Thursday, March 15. Hayden Edmund M also bought $16,191 worth of Camden National Corporation (NASDAQ:CAC) on Thursday, March 15.

Camden National Corporation (NASDAQ:CAC) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>